The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist (BGM0504) in healthy volunteers: A dose‐escalation Phase I study

Jan 22, 2025Diabetes, obesity & metabolism

Safety, body responses, and effects of increasing doses of a new combined hormone therapy (BGM0504) in healthy people

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

A total of 40 volunteers received at least one dose of BGM0504, a drug that may aid in weight loss.

BGM0504, administered in doses ranging from 2.5 mg to 15 mg, showed a linear increase in concentration and exposure over the dose range.
Weight loss percentages from baseline in BGM0504 groups were -3.24%, -6.26%, -7.09%, and -8.30% for the 2.5, 5, 10, and 15 mg doses, respectively.
The drug may have potential benefits for glycaemic control.
Common adverse events included gastrointestinal issues such as vomiting, nausea, decreased appetite, diarrhea, and abdominal distension.
BGM0504 was generally safe and well tolerated based on the study findings.

AI simplified

OBJECTIVE: Previous experiments have demonstrated that BGM0504, a GLP-1R/GIPR dual agonist drug by molecular dynamics-guided optimization, had enhanced agonistic activity compared to tirzepatide. This study aims to investigate its safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) in Chinese healthy volunteers.

METHODS: A randomized, double-blind, placebo-controlled and dose-escalation Phase I study was conducted as follows: a single dose (2.5 mg) and once-weekly administration for 2 weeks to reach target doses (5, 10 and 15 mg) by titration.

RESULTS: A total of 40 volunteers received at least one dose of BGM0504 or placebo. The PK profile of BGM0504 was investigated over a wide dose range and supported once-weekly administration. It was observed that Cand AUC of BGM0504 were linearly proportional to the dose from 2.5-15 mg. The change in body weight (%) from baseline in BGM0504 groups was greater than that in the placebo group, with -3.24%, -6.26%, -7.09% and - 8.30% in 2.5, 5, 10 and 15 mg groups, respectively, indicating a certain dose correlation. Meanwhile, the potential roles of BGM0504 in glycaemic control were also observed. The most frequent adverse events reported were gastrointestinal (vomiting, nausea, decreased appetite, diarrhoea and abdominal distension). max

CONCLUSION: BGM0504 was generally safe and well tolerated with favourable PK profile and potential role in weight loss was also confirmed. These findings support subsequent development of BGM0504 for type 2 diabetes mellitus (T2DM) and obesity.

Full Text

Full text is available at the source.

View full text ↗

The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP ‐1/ GIP receptor agonist (BGM0504) in healthy volunteers: A dose‐escalation Phase I study

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief